CA-19-9 Antigen
Research stageAlso known as CA 19.9 - Carbohydrate antigen 19.9, Cancer antigen 19-9, Carbohydrate antigen 19.9, SIALYL LEWIS A.
Recent clinical, regulatory, research and industry developments relating to this drug.
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- Journal of hepatology1
- Molecular therapy : the journal of the American Society of Gene Therapy1
- Proceedings of the National Academy of Sciences of the United States of America1
- Adeva J1
- Ahuja N1
- Allen PJ1
- Alvaro D1
- Andersen JB1
- Banales JM1
- Braconi C1
- Brand RE1
- Asan Medical Center1
- Biodonostia Health Research Institute1
- Biotech Research and Innovation Centre (BRIC)1
- Cancer Center Amsterdam1
- Center for Cell Engineering1
- Clinica Medica Unit1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as CA-19-9 Antigen in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature